|
1
|
Fineberg D, Jandeleit-Dahm KA and Cooper
ME: Diabetic nephropathy: Diagnosis and treatment. Nat Rev
Endocrinol. 9:713–723. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bloomgarden Z: Questioning glucose
measurements used in the International Diabetes Federation (IDF)
Atlas. J Diabetes. 8:746–747. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mendis S, Davis S and Norrving B:
Organizational update: The world health organization global status
report on noncommunicable diseases 2014; one more landmark step in
the combat against stroke and vascular disease. Stroke.
46:e121–e122. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brenner BM, Cooper ME, de Zeeuw D, Keane
WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z and
Shahinfar S; RENAAL Study Investigators, : Effects of losartan on
renal and cardiovascular outcomes in patients with type 2 diabetes
and nephropathy. N Engl J Med. 345:861–869. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Haller H, Ito S, Izzo JL Jr, Januszewicz
A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruilope LM,
et al: Olmesartan for the delay or prevention of microalbuminuria
in type 2 diabetes. N Engl J Med. 364:907–917. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jermendy G and Ruggenenti P: Preventing
microalbuminuria in patients with type 2 diabetes. Diabetes Metab
Res Rev. 23:100–110. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dugbartey GJ: Diabetic nephropathy: A
potential savior with ‘rotten-egg’ smell. Pharmacol Rep.
69:331–339. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fioretto P, Steffes MW and Mauer M:
Glomerular structure in nonproteinuric IDDM patients with various
levels of albuminuria. Diabetes. 43:1358–1364. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Perkins BA, Ficociello LH, Roshan B,
Warram JH and Krolewski AS: In patients with type 1 diabetes and
new-onset microalbuminuria the development of advanced chronic
kidney disease may not require progression to proteinuria. Kidney
Int. 77:57–64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Flyvbjerg A: The role of the complement
system in diabetic nephropathy. Nat Rev Nephrol. 13:311–318. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fan Y, Lee K, Wang N and He JC: The role
of endoplasmic reticulum stress in diabetic nephropathy. Curr Diab
Rep. 17:172017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Schena FP and Gesualdo L: Pathogenetic
mechanisms of diabetic nephropathy. J Am Soc Nephrol. 16 Suppl
1:S30–S33. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fioretto P and Mauer M: Diabetic
nephropathy: Diabetic nephropathy-challenges in pathologic
classification. Nat Rev Nephrol. 6:508–510. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wagenseil JE and Mecham RP: Vascular
extracellular matrix and arterial mechanics. Physiol Rev.
89:957–989. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
van der Slot-Verhoeven AJ, van Dura EA,
Attema J, Blauw B, Degroot J, Huizinga TW, Zuurmond AM and Bank RA:
The type of collagen cross-link determines the reversibility of
experimental skin fibrosis. Biochim Biophys Acta. 1740:60–67. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Aeschlimann D and Thomazy V: Protein
crosslinking in assembly and remodelling of extracellular matrices:
The role of transglutaminases. Connect Tissue Res. 41:1–27. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dimas GG, Didangelos TP and Grekas DM:
Matrix gelatinases in atherosclerosis and diabetic nephropathy:
Progress and challenges. Curr Vasc Pharmacol. 15:557–565. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Csiszar K: Lysyl oxidases: A novel
multifunctional amine oxidase family. Prog Nucleic Acid Res Mol
Biol. 70:1–32. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kagan HM and Li W: Lysyl oxidase:
Properties, specificity, and biological roles inside and outside of
the cell. J Cell Biochem. 88:660–672. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kiemer AK, Takeuchi K and Quinlan MP:
Identification of genes involved in epithelial-mesenchymal
transition and tumor progression. Oncogene. 20:6679–6688. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mäki JM, Tikkanen H and Kivirikko KI:
Cloning and characterization of a fifth human lysyl oxidase
isoenzyme: The third member of the lysyl oxidase-related subfamily
with four scavenger receptor cysteine-rich domains. Matrix Biol.
20:493–496. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li RK, Zhao WY, Fang F, Zhuang C, Zhang
XX, Yang XM, Jiang SH, Kong FZ, Tu L, Zhang WM, et al: Lysyl
oxidase-like 4 (LOXL4) promotes proliferation and metastasis of
gastric cancer via FAK/Src pathway. J Cancer Res Clin Oncol.
141:269–281. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wu G, Guo Z, Chang X, Kim MS, Nagpal JK,
Liu J, Maki JM, Kivirikko KI, Ethier SP, Trink B and Sidransky D:
LOXL1 and LOXL4 are epigenetically silenced and can inhibit
ras/extracellular signal-regulated kinase signaling pathway in
human bladder cancer. Cancer Res. 67:4123–4129. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jiang WP, Sima ZH, Wang HC, Zhang JY, Sun
LS, Chen F and Li TJ: Identification of the involvement of LOXL4 in
generation of keratocystic odontogenic tumors by RNA-Seq analysis.
Int J Oral Sci. 6:31–38. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Weise JB, Rudolph P, Heiser A, Kruse ML,
Hedderich J, Cordes C, Hoffmann M, Brant O, Ambrosch P, Csiszar K
and Görögh T: LOXL4 is a selectively expressed candidate diagnostic
antigen in head and neck cancer. Eur J Cancer. 44:1323–1331. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Goto Y, Uchio-Yamada K, Anan S, Yamamoto
Y, Ogura A and Manabe N: Transforming growth factor-beta1 mediated
up-regulation of lysyl oxidase in the kidneys of hereditary
nephrotic mouse with chronic renal fibrosis. Virchows Arch.
447:859–868. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Higgins DF, Kimura K, Bernhardt WM,
Shrimanker N, Akai Y, Hohenstein B, Saito Y, Johnson RS, Kretzler
M, Cohen CD, et al: Hypoxia promotes fibrogenesis in vivo via HIF-1
stimulation of epithelial-to-mesenchymal transition. J Clin Invest.
117:3810–3820. 2007.PubMed/NCBI
|
|
28
|
Magri CJ and Fava S: The role of tubular
injury in diabetic nephropathy. Eur J Intern Med. 20:551–555. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Reed MJ, Meszaros K, Entes LJ, Claypool
MD, Pinkett JG, Gadbois TM and Reaven GM: A new rat model of type 2
diabetes: The fat-fed, streptozotocin-treated rat. Metabolism.
49:1390–1394. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tervaert TW, Mooyaart AL, Amann K, Cohen
AH, Cook HT, Drachenberg CB, Ferrario F, Fogo AB, Haas M, de Heer
E, et al: Pathologic classification of diabetic nephropathy. J Am
Soc Nephrol. 21:556–563. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Giunti S, Calkin AC, Forbes JM, Allen TJ,
Thomas MC, Cooper ME and Jandeleit-Dahm KA: The pleiotropic actions
of rosuvastatin confer renal benefits in the diabetic Apo-E
knockout mouse. Am J Physiol Renal Physiol. 299:F528–F535. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim J, Jang HS and Park KM: Reactive
oxygen species generated by renal ischemia and reperfusion trigger
protection against subsequent renal ischemia and reperfusion injury
in mice. Am J Physiol Renal Physiol. 298:F158–F166. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Racusen LC, Solez K, Colvin RB, Bonsib SM,
Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo
AB, et al: The Banff 97 working classification of renal allograft
pathology. Kidney Int. 55:713–723. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bangstad HJ, Osterby R, Hartmann A, Berg
TJ and Hanssen KF: Severity of glomerulopathy predicts long-term
urinary albumin excretion rate in patients with type 1 diabetes and
microalbuminuria. Diabetes Care. 22:314–319. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Drummond K and Mauer M; International
Diabetic Nephropathy Study Group, : The early natural history of
nephropathy in type 1 diabetes: II. Early renal structural changes
in type 1 diabetes. Diabetes. 51:1580–1587. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Matsumae T, Jimi S, Uesugi N, Takebayashi
S and Naito S: Clinical and morphometrical interrelationships in
patients with overt nephropathy induced by non-insulin-dependent
diabetes mellitus. A light- and electron-microscopy study. Nephron.
81:41–48. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Griffen SC, Wang J and German MS: A
genetic defect in beta-cell gene expression segregates
independently from the fa locus in the ZDF rat. Diabetes. 50:63–68.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hempe J, Elvert R, Schmidts HL, Kramer W
and Herling AW: Appropriateness of the Zucker Diabetic Fatty rat as
a model for diabetic microvascular late complications. Lab Anim.
46:32–39. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
El Hajj EC, El Hajj MC, Ninh VK, Bradley
JM, Claudino MA and Gardner JD: Detrimental role of lysyl oxidase
in cardiac remodeling. J Mol Cell Cardiol. 109:17–26. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chronopoulos A, Tang A, Beglova E,
Trackman PC and Roy S: High glucose increases lysyl oxidase
expression and activity in retinal endothelial cells: Mechanism for
compromised extracellular matrix barrier function. Diabetes.
59:3159–3166. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang X, Scott HA, Monickaraj F, Xu J,
Ardekani S, Nitta CF, Cabrera A, McGuire PG, Mohideen U, Das A and
Ghosh K: Basement membrane stiffening promotes retinal endothelial
activation associated with diabetes. FASEB J. 30:601–611. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Raposo B, Rodríguez C, Martínez-González J
and Badimon L: High levels of homocysteine inhibit lysyl oxidase
(LOX) and downregulate LOX expression in vascular endothelial
cells. Atherosclerosis. 177:1–8. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Akiri G, Sabo E, Dafni H, Vadasz Z,
Kartvelishvily Y, Gan N, Kessler O, Cohen T, Resnick M, Neeman M
and Neufeld G: Lysyl oxidase-related protein-1 promotes tumor
fibrosis and tumor progression in vivo. Cancer Res. 63:1657–1666.
2003.PubMed/NCBI
|
|
44
|
Barker HE, Cox TR and Erler JT: The
rationale for targeting the LOX family in cancer. Nat Rev Cancer.
12:540–552. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bonnans C, Chou J and Werb Z: Remodelling
the extracellular matrix in development and disease. Nat Rev Mol
Cell Biol. 15:786–801. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Torres S, Garcia-Palmero I, Herrera M,
Bartolomé RA, Peña C, Fernandez-Aceñero MJ, Padilla G,
Peláez-García A, Lopez-Lucendo M, Rodriguez-Merlo R, et al: LOXL2
is highly expressed in cancer-associated fibroblasts and associates
to poor colon cancer survival. Clin Cancer Res. 21:4892–4902. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Barker HE, Chang J, Cox TR, Lang G, Bird
D, Nicolau M, Evans HR, Gartland A and Erler JT: LOXL2-mediated
matrix remodeling in metastasis and mammary gland involution.
Cancer Res. 71:1561–1572. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Schlötzer-Schrehardt U, Hammer CM, Krysta
AW, Hofmann-Rummelt C, Pasutto F, Sasaki T, Kruse FE and Zenkel M:
LOXL1 deficiency in the lamina cribrosa as candidate susceptibility
factor for a pseudoexfoliation-specific risk of glaucoma.
Ophthalmology. 119:1832–1843. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Braunsmann C, Hammer CM, Rheinlaender J,
Kruse FE, Schäffer TE and Schlötzer-Schrehardt U: Evaluation of
lamina cribrosa and peripapillary sclera stiffness in
pseudoexfoliation and normal eyes by atomic force microscopy.
Invest Ophthalmol Vis Sci. 53:2960–2967. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Schumacher S, Schlötzer-Schrehardt U,
Martus P, Lang W and Naumann GO: Pseudoexfoliation syndrome and
aneurysms of the abdominal aorta. Lancet. 357:359–360. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
French DD, Margo CE and Harman LE: Ocular
pseudoexfoliation and cardiovascular disease: A national
cross-section comparison study. N Am J Med Sci. 4:468–473. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang W, He M, Zhou M and Zhang X: Ocular
pseudoexfoliation syndrome and vascular disease: A systematic
review and meta-analysis. PLoS One. 9:e927672014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhang J, Yang R, Liu Z, Hou C, Zong W,
Zhang A, Sun X and Gao J: Loss of lysyl oxidase-like 3 causes cleft
palate and spinal deformity in mice. Hum Mol Genet. 24:6174–6185.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Alzahrani F, Al Hazzaa SA, Tayeb H and
Alkuraya FS: LOXL3, encoding lysyl oxidase-like 3, is mutated in a
family with autosomal recessive Stickler syndrome. Hum Genet.
134:451–453. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Li J, Gao B, Xiao X, Li S, Jia X, Sun W,
Guo X and Zhang Q: Exome sequencing identified null mutations in
LOXL3 associated with early-onset high myopia. Mol Vis. 22:161–167.
2016.PubMed/NCBI
|
|
56
|
Haase VH: Pathophysiological consequences
of HIF activation: HIF as a modulator of fibrosis. Ann N Y Acad
Sci. 1177:57–65. 2009. View Article : Google Scholar : PubMed/NCBI
|
